Next Article in Journal
Evaluation of the Combined Effects of Stilbenoid from Shorea gibbosa and Vancomycin against Methicillin-Resistant Staphylococcus aureus (MRSA)
Next Article in Special Issue
Metabolism and Pharmacokinetics of the Anti-Tuberculosis Drug Ethionamide in a Flavin-Containing Monooxygenase Null Mouse
Previous Article in Journal
Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer
Previous Article in Special Issue
The Chemical Components of Sesbania grandiflora Root and Their Antituberculosis Activity
Pharmaceuticals 2012, 5(9), 1021-1031; doi:10.3390/ph5091021
Review

Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient

1,*  and 2
1 Grupo de Micobacterias, Unidade de Microbacteriologia, Centro de Malaria e outras Doenças Tropicais (CMDT), Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Rua Junqueira 100, 1349-008 Lisbon, Portugal 2 Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, 6720 Szeged, Hungary
* Author to whom correspondence should be addressed.
Received: 13 August 2012 / Revised: 10 September 2012 / Accepted: 11 September 2012 / Published: 17 September 2012
(This article belongs to the Special Issue Antituberculosis Drugs)
View Full-Text   |   Download PDF [200 KB, uploaded 18 September 2012]   |   Browse Figures

Abstract

This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries.
Keywords: pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; cures the mouse of MDR-Mtb infections; XDR-TB; TDR-TB; cures the human of an XDR-TB infection; mechanisms of action; inhibitor of efflux pumps; enhances killing of intracellular Mtb pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; cures the mouse of MDR-Mtb infections; XDR-TB; TDR-TB; cures the human of an XDR-TB infection; mechanisms of action; inhibitor of efflux pumps; enhances killing of intracellular Mtb
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Amaral, L.; Molnar, J. Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals 2012, 5, 1021-1031.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert